Metabolic Metabolic 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90% of all cases1 Efficacy Empagliflozin survival benefit EMPRISE Study; Effectiveness of Empagliflozin on reducing hospitalization for heart failure EMPRISE Study; Empagliflozin real world effectiveness & Safety EMPULSE Study; in-hospital intiation of Empagliflozin in patients hosptalized for HF with HFrEF or HFpEF, with or without T2D EMPA-KIDNEY study; the study of heart and kidney protection with Empagliflozin in patients with CKD with or without T2D EMPERIAL Studies; effects of Empagliflozin on functional capacity and quality of life in patients with chronic HFrEF or HFpEF with or without T2D EMPA-VISION Study; a mechanistic study to help explain how empagliflozin may improve HF-related outcomes EMPEROR Studies; two dedicated clinical outcomes studies of Empagliflozin for treating patients with HFrEF or HFpEF, with or without T2D 06:35 EMPRISE Study; Empagliflozin real world comparative effictiveness & safety 07:43 EMPA-REG OUTCOME Trial; a true landmark trial and a real game changer Production date: Apr 2019
